scholarly journals PSY160 - REAL WORLD TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PULMONARY ARTERIAL HYPERTENSION IN BRAZIL: A PUBLIC HEALTHCARE DATABASE STUDY

2018 ◽  
Vol 21 ◽  
pp. S463-S464
Author(s):  
H.E. Cavalcanti ◽  
G.S. Julian ◽  
P. Santana ◽  
A. Duva ◽  
A.F. Ballalai
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Resource Utilization ◽  
Real World ◽  
Treatment Patterns ◽  
Public Healthcare ◽  
Healthcare Database ◽  
Database Study ◽  
Pulmonary Arterial

scholarly journals Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database

2018 ◽  
Vol 9 (1) ◽  
pp. 204589401881629 ◽  
Author(s):  
Sean Studer ◽  
Michael Hull ◽  
Janis Pruett ◽  
Eleena Koep ◽  
Yuen Tsang ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Resource Utilization ◽  
Real World ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization ◽  
Treatment Patterns ◽  
Combination Therapies ◽  
Pulmonary Arterial

Several new medications for pulmonary arterial hypertension (PAH) have recently been introduced; however, current real-world data regarding US patients with PAH are limited. We conducted a retrospective administrative claims study to examine PAH treatment patterns and summarize healthcare utilization and costs among patients with newly diagnosed PAH treated in US clinical practice. Patients newly treated for PAH from 1 January 2010 to 31 March 2015 were followed for ≥12 months. Patient characteristics, treatment patterns, healthcare resource utilization, and costs were described. Adherence (proportion of days covered), persistence (months until therapy discontinuation/modification), and the probability of continuing the index regimen were analyzed by index regimen cohort (monotherapy versus combination therapy). Of 1637 eligible patients, 93.8% initiated treatment with monotherapy and 6.2% with combination therapy. The most common index regimen was phosphodiesterase type 5 inhibitor (PDE-5I) monotherapy (70.0% of patients). A total of 581 patients (35.5%) modified their index regimen during the study. Most patients (55.4%) who began combination therapy did so on or within six months of the index date. Endothelin receptor agonists (ERAs) and combination therapies were associated with higher adherence than PDE-5Is and monotherapies, respectively. Healthcare utilization was substantial across the study population, with costs in the combination therapy cohort more than doubling from baseline to follow-up. The majority of patients were treated with monotherapies (most often, PDE-5Is), despite combination therapies and ERAs being associated with higher medication adherence. Index regimen adjustments occurred early and in a substantial proportion of patients, suggesting that inadequate clinical response to monotherapies may not be uncommon.

scholarly journals Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy

10.36469/9812 ◽  
2018 ◽  
Vol 5 (2) ◽  
pp. 206-219 ◽  
Author(s):  
George Ruiz ◽  
Jason Yeaw ◽  
Cassandra A. Lickert ◽  
Ajita P. De ◽  
Rolin L. Wade ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Resource Utilization ◽  
Real World ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization ◽  
Treatment Patterns ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Treatment Modification ◽  
Pulmonary Arterial

Background: Pulmonary arterial hypertension (PAH) is described by proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance, right ventricular failure, and death. Research confirms long-term improvement in composite morbidity and mortality endpoints on some endothelin receptor antagonists alone and in combination with phosphodiesterase type 5 inhibitors (PDE-5is) but not with PDE-5i monotherapy. While current treatment guidelines incorporate these findings, a substantial number of patients are started or maintained on PDE-5i monotherapy.</p> Objectives: This study describes real-world clinical practice and treatment patterns with PDE-5i monotherapy including events indicative of clinical worsening, treatment modifications, adherence, allcause healthcare resource utilization, and costs. Methods: This retrospective study analyzed PharMetrics Plus claims data including 150 million lives; study period was January 1, 2009 through December 31, 2013. Eligible patients were ≥18 years with ≥1 inpatient or ≥2 outpatient claims ≥30 days apart, a diagnosis of pulmonary hypertension or other chronic pulmonary heart disease, and an initial PDE-5i prescription. To include only World Health Organization group 1 PAH patients, ≥1 encounter for right-heart catheterization or Doppler echocardiogram was required during the pre-index period. Results: PDE-5i monotherapy for PAH treatment was associated with high treatment modification rates, low adherence, increased healthcare resource utilization, and high costs. At 12 months post index, 41.5% of patients experienced treatment modification. For the index therapy, 47% of patients had ≥80% adherence to therapy. Almost 50% of patients had ≥1 hospitalization, with costs increased three fold to $197 111 compared to $59 164 for non-hospitalized patients. Conclusions: Initial treatment with PDE-5i monotherapy was associated with substantial direct medical costs, including hospitalizations and emergency department visits, low therapy adherence and a high rate of treatment modifications.

scholarly journals Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension

2021 ◽  
Author(s):  
Adesuwa Ogbomo ◽  
Yuen Tsang ◽  
Furaha Kariburyo ◽  
Wan-Lun Tsai ◽  
Sumeet Panjabi
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Real World ◽  
Treatment Patterns ◽  
Hospitalized Patients ◽  
Pulmonary Arterial

scholarly journals PCV152 TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN THE US

2010 ◽  
Vol 13 (3) ◽  
pp. A178-A179
Author(s):  
M Angalakuditi ◽  
E Buysman ◽  
T Bancroft ◽  
A Beardsworth
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Resource Utilization ◽  
Treatment Patterns ◽  
The Us ◽  
Pulmonary Arterial

Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States

2010 ◽  
Vol 13 (3) ◽  
pp. 393-402 ◽  
Author(s):  
Mallik Angalakuditi ◽  
Eric Edgell ◽  
Anthony Beardsworth ◽  
Erin Buysman ◽  
Tim Bancroft
Keyword(s):  
United States ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Resource Utilization ◽  
The United States ◽  
Treatment Patterns ◽  
Pulmonary Arterial

TREATMENT PATTERNS IN PULMONARY ARTERIAL HYPERTENSION: CHANGES IN CLINICAL PRACTICE OVER TIME USING REAL-WORLD EVIDENCE FROM THE COMBINED OPUS/ORPHEUS DATA SETS

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A2194-A2196
Author(s):  
Kelly Chin ◽  
Richard Channick ◽  
Vallerie McLaughlin ◽  
Chad Miller ◽  
Megan Flynn ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Real World ◽  
Treatment Patterns ◽  
Data Sets ◽  
Real World Evidence ◽  
Pulmonary Arterial ◽  
Over Time
Sign in / Sign up

Export Citation Format

Share Document